Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis...

Full description

Bibliographic Details
Main Authors: Laurel Goldin, Ty Elders, Leslie Werhane, Kimberly Korwek, Russell Poland, Jeffrey Guy
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Sars-Co-V-2
monoclonal antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S120197122100713X

Similar Items

Similar Items